<DOC>
	<DOCNO>NCT00826891</DOCNO>
	<brief_summary>This single arm , open-label study woman China Advanced ( stage IVB ) Recurrent Persistent cervical cancer ⑴assess response rate ( i.e. , CR + PR ) Cisplatin combined Topotecan treatment advance ( stage IVB ) recurrent persistent Cervical cancer ; ⑵assess toxicity CT regimen treatment cervical cancer . Prior treatment , write informed consent obtain patient . Eligible patient assign CT regimen . The CT regimen topotecan 0.75 mg/m2 IV 30minutes day 1 , 2 , 3 ; follow cisplatin 50 mg/m2 IV day1 , repeat every 21 day . The study consist two phase : safety run-in phase study phase .</brief_summary>
	<brief_title>Study Cisplatin Cervical Cancer Stage IVB</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>woman advance recurrent persistent carcinoma uterine cervical unsuitable candidate curative treatment surgery and/or radiotherapy . Histologic type include squamous , adenosquamous , adenocarcinoma cervia . Patients must least 18 year old . Measurable and/or evaluable disease parameter document record use clinical evaluation ( use CT pathologic node present ) . Life expectation great 3 month . Patients must adequate organ function . Patients without history sensitivity camptothecin platinum . Patients nonchildbearing potential , consistent correct use method birth control 2 week prior administration first dose study medication 28 day final dose observational medication . performance status 0 2 ; recover effect recent surgery , chemoradiotherapy , radiotherapy ; free clinically significant infection . Written informed consent Patients uncontrolled infection . Patients concurrent severe medical problem unrelated malignancy would expose patient extreme risk . Patients receive another investigational drug within 30 day prior study entry . Patients receive concurrent chemotherapy , hormonal , immunotherapy radiotherapy . Radiotherapy palliation relate bone metastasis permit . Patients history allergic reaction compound chemically related topotecan platinum . Patients pregnant lactate Concomitant malignancy previous malignancy within last five year , exception adequately treat basal squamous cell carcinoma skin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>